ITB-Iplus/GDF-MED/2025/1 _Annex C. List of priority countries for TB medicines registration updated
ITB-Iplus/GDF-MED/2025/1 _Annex B - List and technical specifications of products requested
ITB-Iplus/GDF-MED/2025/1_Annex A. Financial Bid Response Form
ITB-Iplus/GDF-MED/2025/1_ITB document pretomanid 200mg
Closing the gaps in childhood TB detection

Creswell, J.; Colvin, C.

TPMAT Recommendations - Round 30 (EOI Released February 2025)
Integrating socio-economic support into drug-resistant TB care to optimise treatment outcomes

Limo, J.; Pahe, C.; Kathure, I.; Ndungu, L.; Mahihu, A.; Mwashumbe, C.; Mueni, E. and Momanyi, H.

2025-01_QA Notice_USFDA Warning letter_Mylan Indore Pithampur site
Enhancing tuberculosis case notifications through mapping sales of medicine in the private sector: a quasi-experimental study in Punjab province, Pakistan

Beatrice Kirubi, Kinz Ul Eman, Usman R. Lodhi, Razia K. Fatima, Ghulam Nabi Kazi, Tahmeena Tahmeena, Syed Karam Shah and Jacob Creswell

ITB document ITB-Iplus/GDF-MED/2024/3